Century Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Century Therapeutics, Inc. (IPSC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $101.60 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2023-03-16
- Century Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2022-12-31 was $101.60M.
- Century Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2022-09-30 was $0.00.
- Century Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2022-06-30 was $0.00.
- Century Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2022-03-31 was $0.00.
- Century Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $101.60M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|---|---|---|
| 2022-12-31 | $101.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $101.60M derived: sum of 2 quarters · filed 2023-03-16 | $101.60M derived: sum of 3 quarters · filed 2023-03-16 | $101.60M 10-K · filed 2023-03-16 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |